Taiho acquires Yondelis for Japan
This article was originally published in Scrip
Executive Summary
Taiho has acquired exclusive Japanese development and marketing rights to PharmaMar's antitumour compound Yondelis (trabectedin). The Spanish Zeltia group's subsidiary will receive ¥1 billion ($10.2 million) up front, plus milestones and double-digit sales royalties.